Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ETONNASDAQ:MNPRNASDAQ:SAVANASDAQ:TRILNASDAQ:TRVI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$3.22+0.3%$3.93$2.42▼$5.81$82.72M1.1766,361 shs4,652 shsMNPRMonopar Therapeutics$0.64-2.6%$0.75$0.27▼$1.75$11.16M1.194.28 million shs29,332 shsSAVACassava Sciences$21.36+3.0%$21.50$12.32▼$32.10$923.74M-0.45758,235 shs290,291 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsTRVITrevi Therapeutics$2.45-7.5%$3.00$0.97▼$4.00$168.95M0.86274,488 shs82,163 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals-2.13%+2.23%-17.27%-27.70%-8.55%MNPRMonopar Therapeutics+1.08%+1.08%-7.46%+77.57%-40.81%SAVACassava Sciences+0.92%-2.49%+5.28%-15.62%+32.58%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%TRVITrevi Therapeutics-7.02%+2.71%-20.90%+99.25%-9.56%See this before next week's Fed meeting (Ad)See this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETONEton Pharmaceuticals2.1126 of 5 stars3.55.00.00.00.00.80.0MNPRMonopar Therapeutics2.4146 of 5 stars3.55.00.00.00.61.70.6SAVACassava Sciences3.5026 of 5 stars3.51.00.04.71.80.80.6TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics2.495 of 5 stars3.54.00.00.01.43.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals3.00Buy$10.00210.56% UpsideMNPRMonopar Therapeutics3.00Buy$2.00212.65% UpsideSAVACassava Sciences3.00Buy$124.00480.52% UpsideTRILTrillium TherapeuticsN/AN/AN/AN/ATRVITrevi Therapeutics3.00Buy$8.50246.94% UpsideCurrent Analyst RatingsLatest ETON, TRVI, SAVA, TRIL, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.004/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$31.64M2.61$0.00 per share1,026.35$0.60 per share5.37MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ATRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)MNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.32N/A12.79N/AN/A-57.53%-52.58%5/6/2024 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ATRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)Latest ETON, TRVI, SAVA, TRIL, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/A3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/A3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton PharmaceuticalsN/A1.651.60MNPRMonopar TherapeuticsN/A4.174.17SAVACassava SciencesN/A9.139.13TRILTrillium TherapeuticsN/A19.8219.82TRVITrevi TherapeuticsN/A15.0315.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%MNPRMonopar Therapeutics1.83%SAVACassava Sciences38.05%TRILTrillium Therapeutics87.15%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals13.16%MNPRMonopar Therapeutics41.60%SAVACassava Sciences12.20%TRILTrillium Therapeutics9.10%TRVITrevi Therapeutics27.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableETON, TRVI, SAVA, TRIL, and MNPR HeadlinesSourceHeadlineCritical Analysis: Pliant Therapeutics (NASDAQ:PLRX) vs. Trevi Therapeutics (NASDAQ:TRVI)americanbankingnews.com - April 20 at 2:16 AMTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.com - April 18 at 10:56 AMTwo stand-ups to perform at Trevi this Saturdaysaultstar.com - April 17 at 7:02 PMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferencefinance.yahoo.com - April 9 at 9:54 AMTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferenceprnewswire.com - April 9 at 7:30 AMTrevi Therapeutics appoints new VP for clinical developmentuk.investing.com - April 4 at 7:56 PMWhy Trevi Therapeutics (TRVI) Stock Might be a Great Pickzacks.com - April 4 at 9:31 AMTrevi Therapeutics to Participate in Upcoming April Eventsprnewswire.com - April 4 at 7:30 AMTrevi piles into Melbourne’s Link megaproject with four hyrdromillsglobalconstructionreview.com - April 3 at 10:24 AMCity worker cleans coins at Trevi Fountain in Romechinaview.cn - April 2 at 8:36 PMTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Teamfinance.yahoo.com - April 2 at 10:35 AMTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itmsn.com - March 29 at 7:12 PMTrevi Italian Restaurant at Forum Shops unexpectedly closesmsn.com - March 28 at 9:44 PMProminent Trevi Italian Restaurant Abruptly Closes at the Forum Shopsmsn.com - March 27 at 1:26 PMTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 21 at 11:14 AMTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 21 at 7:22 AMTrevi Therapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 9:21 PMTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023msn.com - March 20 at 9:21 PMTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trialsfinance.yahoo.com - March 20 at 9:21 PMGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossamsn.com - March 17 at 10:44 PMGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossamsn.com - March 16 at 4:38 PMWhat happens to the coins tossed into Rome's Trevi Fountain?astroawani.com - March 15 at 11:04 PMTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024finance.yahoo.com - March 13 at 8:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Trillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.